Burden of 30 cancers among men: Global statistics in 2022 and projections for 2050 using population-based estimates.

BACKGROUND: Men exhibit higher prevalence of modifiable risk factors, such as smoking and alcohol consumption, leading to greater cancer incidence and lower survival rates. Comprehensive evidence on global cancer burden among men, including disparities by age group and country, is sparse. To address this, the authors analyzed 30 cancer types among men in 2022, with projections estimated for 2050. METHODS: The 2022 GLOBOCAN estimates were used to describe cancer statistics for men in 185 countries/territories worldwide. Mortality-to-incidence ratios (MIRs) were calculated by dividing age-standardized mortality rates by incidence rates. RESULTS: In 2022, a high MIR (indicating poor survival) was observed among older men (aged 65 years and older; 61%) for rare cancer types (pancreatic cancer, 91%) and in countries with low a Human Development Index (HDI; 74%). Between 2022 and 2050, cancer cases are projected to increase from 10.3 million to 19 million (≥84%). Deaths are projected to increase from 5.4 million to 10.5 million (≥93%), with a greater than two-fold increase among men aged 65 years and older (≥117%) and for low-HDI and medium-HDI countries/territories (≥160%). Cancer cases and deaths are projected to increase among working-age groups (≥39%) and very-high-HDI countries/territories (≥50%). CONCLUSIONS: Substantial disparities in cancer cases and deaths were observed among men in 2022, and these are projected to widen by 2050. Strengthening health infrastructure, enhancing workforce quality and access, fostering national and international collaborations, and promoting universal health coverage are crucial to reducing cancer disparities and ensuring cancer equity among men globally.

Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January-March 2022.

Our analysis of data collected from multiple epidemics in Hong Kong indicated a shorter serial interval and generation time of infections with the SARS-CoV-2 Omicron variant. The age-specific case-fatality risk for Omicron BA.2.2 case-patients without complete primary vaccination was comparable to that of persons infected with ancestral strains in earlier waves.

Reported effectiveness of COVID-19 monovalent booster vaccines and hybrid immunity against mild and severe Omicron disease in adults: A systematic review and meta-regression analysis.

Background: Waning of COVID-19 vaccine efficacy/effectiveness (VE) has been observed across settings and epidemiological contexts. We conducted a systematic review of COVID-19 VE studies and performed a meta-regression analysis to improve understanding of determinants of waning. Methods: Systematic review of PubMed, medRxiv and the WHO-International Vaccine Access Center database summarizing VE studies on 31 December 2022. Studies were those presenting primary adult VE data from hybrid immunity or third/fourth mRNA COVID-19 monovalent vaccine doses [due to limited data with other vaccines] against Omicron, compared with unvaccinated individuals or individuals eligible for corresponding booster doses but who did not receive them. We used meta-regression models, adjusting for confounders, with weeks since vaccination as a restricted cubic spline, to estimate VE over time since vaccination. Results: We identified 55 eligible studies reporting 269 VE estimates. Most estimates (180/269; 67 %) described effectiveness of third dose vaccination; with 48 (18 %) and 41 (15 %) describing hybrid immunity and fourth dose effectiveness, respectively, mostly (200; 74 %) derived from test-negative design studies. Most estimates (176/269; 65 %) reported VE compared with unvaccinated comparison groups. Estimated VE against mild outcomes declined following third dose vaccination from 62 % (95 % CI: 58 % - 66 %) after 4 weeks to 48 % (41 % - 55 %) after 20 weeks. Fourth dose VE against mild COVID-19 declined from 48 % (41 % - 56 %) after 4 weeks to 47 % (19 % - 65 %) after 20 weeks. VE for severe outcomes was higher and declined in the three-dose group from 90 % (87 % - 92 %) after 4 weeks to 70 % (65 - 74 %) after 20 weeks. Conclusions: Time-since vaccination is an important determinant of booster dose VE, a finding which may support seasonal COVID-19 booster doses. Integration of VE and immunological parameters - and longer-term data including from other vaccine types - are needed to better-understand determinants of clinical protection.